NL-OMON37342已完成不适用
Phase I, single-centre, randomised, placebo-controlled, double-blinded study, with single ascending dose and multiple dose at maximum tolerated dose, evaluating the safety, tolerability and pharmacokinetics of ALX-0171, administered by pulmonary inhalation, in healthy male volunteers - ALX-0171 Phase I study in healthy male volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Ablynx NV
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy male volunteers
- •- Age between 18 - 55 years
- •- BMI between 18.0 - 30.0 kg/m2
- •- Only non-smokers
排除标准
- •Suffering from: Hepatitis B or C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study of in case of donating more than 1.5 liter of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
Phase I, Single-Center, Randomized, Placebo-Controlled, Double-Blinded Study with Single Ascending Doses, Evaluating the Safety and Tolerability of T20K, Administered by a 1-hr IV Infusion in Healthy Male VolunteersMultiple SclerosisNL-OMON48273Cyxone AB40
已完成
不适用
A phase I, mono-center, randomized, placebo and comparator controlled, single blind, rising dose, clinical study to determine single dose pharmacokinetics, pharmacodynamics, safety and tolerability of four doses of FSH-GEX* according to adaptive design (25, 75, 150 and 300 IU) administered subcutaneously in healthy pituitary-suppressed female volunteers10013356InfertilityNL-OMON36196Glycotope GmbH18
已完成
1 期
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy VolunteersChronic PainACTRN12617001330336Xgene Pharmaceutical Inc.50
进行中（未招募）
1 期
A Phase I/II, randomised, multicentre, placebo-controlled, partially-blinded, parallel-group study to assess the safety, tolerability and immune response following vaccination with ImmunoseTM FLU in older adults (age 50 to 75 years)MedDRA version: 20.0 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsInfluenzaEUCTR2017-004376-64-SEEurocine Vaccines AB300
已完成
1 期
A Phase 1 Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GLY-200 in Healthy Adult SubjectsMetabolic and Endocrine - DiabetesType 2 DiabetesACTRN12621000800820Glyscend Pty Ltd64